RESUMO
This study explored the association between health literacy, barriers to breast cancer screening, and breast screening participation for women from culturally and linguistically diverse (CALD) backgrounds. English-, Arabic- and Italian-speaking women (n = 317) between the ages of 50 to 74 in North West Melbourne, Australia were recruited to complete a survey exploring health literacy, barriers to breast cancer screening, and self-reported screening participation. A total of 219 women (69%) reported having a breast screen within the past two years. Results revealed that health literacy was not associated with screening participation. Instead, emotional barriers were a significant factor in the self-reported uptake of screening. Three health literacy domains were related to lower emotional breast screening barriers, feeling understood and supported by healthcare providers, social support for health and understanding health information well enough to know what to do. Compared with English- and Italian-speaking women, Arabic-speaking women reported more emotional barriers to screening and greater challenges in understanding health information well enough to know what to do. Interventions that can improve breast screening participation rates should aim to reduce emotional barriers to breast screening, particularly for Arabic-speaking women.
Assuntos
Neoplasias da Mama/diagnóstico , Diversidade Cultural , Detecção Precoce de Câncer/psicologia , Letramento em Saúde , Idoso , Detecção Precoce de Câncer/estatística & dados numéricos , Feminino , Humanos , Pessoa de Meia-Idade , VitóriaRESUMO
OBJECTIVE: To establish a detection and intervention strategy in order to reduce the number of non-steroidal anti-inflammatory drug (NSAIDs) users at risk of gastropathy from receiving either inadequate or no gastroprotection. SETTING: Community Pharmacies in Valencia, Spain. METHOD: Prospective longitudinal intervention study without control group carried out by 79 Community Pharmacies. Patients over 18 who asked for any systemic NSAID were interviewed according to standard procedure. Pharmacist intervention was carried out when a patient at risk of serious NSAID-induced gastrointestinal complications due to inadequate or no gastric protection was identified. The doctor responsible was informed in order to then be able to assess the need to prescribe gastroprotection or change it if inadequate. In the case of over-the-counter (OTC) drugs, pharmacist intervention mainly involved replacing NSAIDs for safer medications. MAIN OUTCOME MEASURE: Firstly, the number of patients who had no prescribed gastroprotection or inadequate gastroprotection was determined. Pharmacist intervention then brought about changes in pharmacotherapy in this situation. RESULTS: Of the 6,965 patients who asked for NSAIDs during the study period, 3,054 (43.9%) presented NSAID gastropathy risk factors. 35.6% of the latter (1,089) were not prescribed gastroprotection or were prescribed inadequate gastroprotection. Pharmacist intervention was carried out in 1,075 of these cases. On 391 occasions such risk situations were reported to doctors, who accepted pharmacist intervention on 309 occasions (79.0%) and then either prescribed gastroprotection (77% of cases); changed it (13.9%); withdrew the NSAID (5.8%) or substituted it (3.2%). 235 Pharmacist interventions took place when dispensing OTC NSAIDs. CONCLUSION: Our strategy allowed us to identify a large number of patients who asked for NSAIDs in Community Pharmacies and who were at risk of NSAID gastropathy, as they received either inadequate gastroprotection or no gastroprotection whatsoever. Moreover, the pharmacist intervention carried out has reduced the number of these risk situations.
Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Serviços Comunitários de Farmácia , Gastroenteropatias/prevenção & controle , Farmacêuticos , Adolescente , Adulto , Idoso , Feminino , Fármacos Gastrointestinais/uso terapêutico , Gastroenteropatias/induzido quimicamente , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Medicamentos sem Prescrição/efeitos adversos , Papel Profissional , Estudos Prospectivos , Fatores de Risco , Espanha/epidemiologia , Adulto JovemRESUMO
La acropigmentación reticulada de Kitamura (ARK) es un genodermatosis de herencia autosómica dominante, con expresión y penetrancia variables. Se caracteriza por presentar máculas hiperpigmentadas de 1 a 4 milímetros de diámetro, deprimidas, similares a efélides, con patrón reticulado, que comienzan en las regiones acrales y posteriormente pueden extenderse en forma centrípeta. Fue descripta por Kitamura et al. en 1943 y, en 1976, Griffiths publicó siete casos en los que analizó los antecedentes familiares y dedujo el carácter genético de la patología. El diagnóstico de ARK se realiza en forma clínica e histopatológica, observándose al microscopio óptico atrofia epidérmica y aumento del número de los melanocitos y de melanina en la capa basal. Debe plantearse el diagnóstico diferencial con la acropigmentación de Dohi (APD), que consiste en máculas hiper e hipopigmentadas en la misma localización, a nivel histológico estas presentan aumento de melanina en la capa basal de la epidermis con número de melanocitos conservados que alterna con regiones de falta de pigmento así como ausencia de pits palmares. Y, también, debe diferenciarse de la enfermedad de Dowling-Degos (EDD) que presenta máculas hiperpigmentadas reticuladas predominantemente en los pliegues. Estas entidades se describen con más frecuencia en poblaciones orientales, no así en nuestro grupo étnico. Presentamos el caso de un niño argentino de tres años de edad, con clínica y biopsia de piel compatibles con ARK, sin antecedentes familiares de esta entidad.
Reticulate acropigmentation of Kitamura (ARK) is a pigmentary genodermatosis of autosomal dominant trait, with variable expresion and penetrance. It is characterized by reticulate patterns of hiperpigmented freckel-like atrophic macules of 1-4 mm, in acral areas, subsequently spreading over the body, with palmar pits. First described by Kitamura et al. in 1943; Griffiths reported in 1976 seven cases and described its inheritance pattern. Microscopic examination of ARK lesions shows epidermic atrophy with increased number of melanocytes and melanin in the basal layer. The main differential diagnosis is with Dohi acropigmentation (DA) whose clinical features are hyperpigmented and hypopigmented reticulate macules in the same location, without palmar pits and which histopathology shows increased melanin in the basal layer and epidermis with normal number of melanocytes and areas with absence of melanin. ARK must also be differentiated from Dowling-Degos disease (DDD) that presents hyperpigmented reticulated macules predominantly located on flexural sites. These entities are frequent in Japanese population but not in ours. We report an Argentinian 3-year-old boy, without family history of ARK and with clinical and histopathological features of this entity.